Gilead spends $1.28bn on PepStar’s potential Icotyde rival
Gilead Sciences acquired global rights to PepStar Therapeutics' oral IL-23 receptor inhibitor for $1.28bn, aiming to rival Johnson & Johnson's Icotyde. The lead asset, HCXT-2001, is in Phase I trials and targets inflammatory bowel disease. Gilead's CMO highlights its potential for differentiation. Jefferies analysts view the deal positively, suggesting HCXT-2001 could offer clinical benefits in combination with Gilead's emvistegrast.
How this was made
The 30-second read
Why it matters
The deal diversifies Gilead's revenue sources beyond antivirals, positioning it in the growing IBD and autoimmune market.
Market read
A major pipeline‑expanding acquisition that could lift Gilead's stock and affect the broader biotech sector.
What to watch
Integration costs, regulatory pathways for oral biologics, and possible competition from Johnson & Johnson's Icotyde may limit upside.
Background
Gilead is in a run of strategic acquisitions in 2026 to offset upcoming virology patent expiries, including recent CAR‑T and ADC deals.
Ticker impact
Gilead Sciences announced a $1.28 bn upfront deal to acquire global rights to PepStar's oral IL‑23 receptor inhibitor program, including lead asset HCXT‑2001 in Phase I.
likely upward pressure as investors price in a new growth asset and pipeline diversification
Large upfront payment signals strong confidence; market typically rewards biotech deals that add novel oral modalities.
Market effects
strengthens the biotech/biopharma sector's focus on oral immunology therapies and may spur competitor activity in IL‑23 space
adds a high‑profile US‑China collaboration, highlighting cross‑border drug development opportunities
potentially influences global inflammation drug market dynamics and investor sentiment toward pipeline‑rich pharma stocks
Counterpoint
The Phase I asset carries high clinical risk; the large cash outlay could strain Gilead's balance sheet if development stalls.
Key entities
- companyGilead Sciences
US‑listed biopharma acquiring oral IL‑23 inhibitor rights
- companyPepStar Therapeutics
Shanghai‑based developer of macrocyclic peptide IL‑23R inhibitor
